Analysts Raise Price Targets for Axogen After Q3 Results
Truist and Barclays lifted Axogen price targets to $60, from $53 and $50, respectively; Wells Fargo raised its target to $56 from $48. Truist and Barclays maintained Buy ratings.
Following Axogen's third-quarter 2026 financial results, several analysts have updated their outlooks on the company. Truist Securities maintained a Buy rating while increasing its price target to $60 from $53. Barclays also maintained a Buy rating and raised its price target to $60 from $50. Additionally, Wells Fargo increased its price target for the company to $56 from $48.
These adjustments reflect analyst reactions to the company's recent performance and updated financial guidance.